We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

QuantuMDx Contracts ITL for Second Phase of Q-POC™ Development

QuantuMDx Contracts ITL for Second Phase of Q-POC™ Development

QuantuMDx Contracts ITL for Second Phase of Q-POC™ Development

QuantuMDx Contracts ITL for Second Phase of Q-POC™ Development

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "QuantuMDx Contracts ITL for Second Phase of Q-POC™ Development"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

QuantuMDx and ITL will continue their successful partnership by expanding the scope of the development project to deliver the exciting and disruptive Q-POC™, QuantuMDx’s handheld DNA analyzer for 15-20 minute diagnostics by the patient’s side.

Pre-Alpha Prototype
ITL partnered with QuantuMDx in 2014 and has since completed the first phase of the development project. The expanded project will now look to further develop the Company’s innovative proprietary sample preparation technologies with an initial focus on processing finger-prick blood samples, but with a view to expanding this further to include the analysis of low copy number pathogens in large samples.

Moving to Phase Two
ITL will now focus on prototyping, testing and optimizing the key device components ahead of moving the Q-POC™ device into clinical testing...Crucially, automated sample preparation will be included within the cartridges in order to achieve the QuantuMDx’s goal of whole sample to result diagnosis in 15-20 minutes.

The Future
While QuantuMDx is primarily a device developer and aims to license their technology to assay developers, ITL is supporting the Company in developing a range of infectious disease, companion diagnostic and tumour profiling assays to demonstrate the range of potential applications. Moreover the Company is expecting to license component technologies, such as its DNA extraction technology, to strategic partners so that it can maximize its return on investment and generate early revenue.

This exciting development phase will bring Q-POC™ to clinical testing leading eventually to the point of commercialization.

QuantuMDx CSO Jonathan O’Halloran said “Working with ITL throughout 2014 has been a joy. They are dedicated, thoughtful and meticulous in their work, and our continued collaboration will be a great asset to QuantuMDx.”